首页> 美国卫生研究院文献>Springer Open Choice >Absence of Drug–Drug Interactions Between Luseogliflozin a Sodium–Glucose Co-transporter-2 Inhibitor and Various Oral Antidiabetic Drugs in Healthy Japanese Males

【2h】

Absence of Drug–Drug Interactions Between Luseogliflozin a Sodium–Glucose Co-transporter-2 Inhibitor and Various Oral Antidiabetic Drugs in Healthy Japanese Males

机译：在健康的日本男性中葡糖苷钠葡萄糖-共转运蛋白2抑制剂与各种口服降糖药之间没有药物相互作用

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

IntroductionWe investigated the possibilities of drug–drug interactions between luseogliflozin, a sodium–glucose co-transporter-2 inhibitor, and oral antidiabetic drugs (OADs) in healthy Japanese males.

机译：简介我们研究了钠葡糖共转运蛋白2抑制剂luseogliflozin与健康日本男性口服降糖药（OADs）之间药物相互作用的可能性。

著录项

期刊名称 Springer Open Choice
作者
Takashi Sasaki; Yutaka Seino; Atsushi Fukatsu; Michito Ubukata; Soichi Sakai; Yoshishige Samukawa;
展开▼
作者单位

展开▼
年(卷),期 -1(32),5
年度 -1
页码 404–417
总页数 14
原文格式 PDF
正文语种
中图分类外科学;
关键词
Drug–drug interactions Luseogliflozin Sodium glucose co-transporter 2 (SGLT2) Type 2 diabetes mellitus;

机译：药物相互作用;路格列净;钠葡萄糖共转运蛋白2（SGLT2）;2型糖尿病;

相似文献

外文文献
中文文献
专利

1. Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males [J] . Sasaki Takashi, Seino Yutaka, Fukatsu Atsushi, Advances in therapy. . 2015,第5期

机译：在健康的日本男性中，葡糖苷钠-葡萄糖共转运蛋白2抑制剂Luseogliflozin与各种口服降糖药之间没有药物相互作用
2. Replacement Effects and Budget Impacts of Insurance Coverage for Sodium-Glucose Co-Transporter-2 Inhibitors on Oral Antidiabetic Drug Utilization [J] . Chen Hsiang-Yin, Chiu Pei-Yin, Chang Ching-Jun, Clinical drug investigation . 2018,第12期

机译：钠葡萄糖共转运蛋白-2抑制剂对口腔抗糖尿病药物利用的替代效果和预算影响
3. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. [J] . Idris I, Donnelly R Diabetes, obesity & metabolism . 2009,第2期

机译：钠-葡萄糖共转运蛋白2抑制剂：一种新兴的口服抗糖尿病药物。
4. Eudragit E Increases Oral Absorption of YM466 by Inhibiting Drug-bile salt Interactions [C] . Shigeo Takemura, Shunsuke Watanabe, Hiromu Kondou, Annual meeting exposition of the Controlled Release Society . 2005

机译：Eudragit E通过抑制药物-胆盐相互作用提高YM466的口服吸收
5. Mechanisms Underlying Cardiovascular Benefits of Sodium Glucose Co-transporter-2 Inhibitors: Myocardial Substrate or Sodium/Hydrogen Exchanger? [D] . Baker, Hana Elisabeth. 2020

机译：葡萄糖共转运蛋白-2抑制剂的心血管益处潜在的机制：心肌基质或钠/氢气交换器？
6. No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone a Peroxisome Proliferator-Activated Receptor-γ Agonist in Healthy Subjects [O] . Yu Kyong Kim, Jun Gi Hwang, Min Kyu Park 2021

机译：在健康受试者中钠葡萄糖共转运蛋白-2抑制剂Empagliflozin和Lobeglitazone之间没有相关的药代动力学药物 - 药物 - 药物 - 药物 - 药物 - 活血分子激活的受体-γ激动剂
7. Absence of Drug–Drug Interactions Between Luseogliflozin, a Sodium–Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males [O] . 2015

机译：在健康的日本男性中，没有葡糖脲，钠-葡萄糖共转运蛋白2抑制剂与各种口服降糖药之间的药物相互作用

Absence of Drug–Drug Interactions Between Luseogliflozin a Sodium–Glucose Co-transporter-2 Inhibitor and Various Oral Antidiabetic Drugs in Healthy Japanese Males

摘要

著录项

相似文献

相关主题

期刊订阅